Stock data
| Market cap. | SEK296.4m |
| Last close | SEK1.62 |
| High / Low (52 weeks) | SEK5.1 / SEK1.2 |
| Stock market listing | US |
| Forecast net cash (SEKm) | 31.2 |
| Forecast gearing ratio (%) | N/A |
| Team | Healthcare |
| Sector | Pharmaceuticals & healthcare |
Price performance
| % | 1m | 3m | 12m |
|---|---|---|---|
| Actual | 8.9 | (44.2) | (24.5) |
| Relative * | 3.8 | (47.4) | (27.1) |
* % Relative to local index
Other companies in sector Show
Company news
NeuroVive Pharmaceutical AB Year End Report January - December 2017Tue, 20 Feb 2018 07:41:15 GMT |
Amendment: Resolutions From Annual General Meeting in NeuroVive Pharmaceutical ...Fri, 27 Apr 2018 12:22:30 GMT |
NeuroVive Pharmaceutical AB Interim Report January - September 2017Tue, 21 Nov 2017 07:43:30 GMT |
NeuroVive Pharmaceutical AB Publishes 2016 Annual ReportThu, 23 Mar 2017 08:08:15 GMT |
Listing of unit rights and paid subscription units in NeuroVive Pharmaceutical ...Mon, 09 Apr 2018 06:56:15 GMT |
Investment summary
NeuroVive Pharmaceutical is a mitochondrial medicine specialist. NeuroVive’s core portfolio targets orphan indications: traumatic brain injury with NeuroSTAT, various genetic mitochondrial diseases with KL1333 and NVP015, and mitochondrial myopathy with NVP025. NeuroVive has received positive feedback from the FDA on its NeuroSTAT TBI development plan including the design of the Phase IIb proof-of-concept study. The study is expected to start in 2019. The second most advanced product KL1333, in-licensed from Yungjin Pharm in May 2017, demonstrated positive results in the Phase I trial in South Korea and NeuroVive is planning to start a Phase Ib study in H119. A recent highlight is the out-licensing of a subset of compounds from NVP015 program for localized treatment of LHON to BridgeBio Pharma for a deal value of around $60m. Other products for out-licensing include NV556 and NVP022 for NASH and NVP024 for hepatocellular carcinoma.
Last updated on 01/02/2019
| Y/E Dec | Revenue (SEKm) | EBITDA (SEKm) | PBT (SEKm) | EPS (fd) (öre) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2016A | 0.0 | (69.9) | (70.7) | (172.27) | N/A | N/A |
| 2017A | 0.6 | (67.9) | (70.1) | (149.31) | N/A | N/A |
| 2018E | 1.5 | (69.3) | (69.7) | (102.28) | N/A | N/A |
| 2019E | 1.5 | (132.8) | (133.0) | (106.64) | N/A | N/A |
Last updated on 17/12/2018
Latest research
SEK124m rights issue underway 80% guaranteed
Update | Pharmaceuticals & healthcare | 17/12/2018
Licensing deal and R&D pipeline progress
Outlook | Pharmaceuticals & healthcare | 05/10/2018
KL1333 Ph I positive; rights issue oversubscribed
Update | Pharmaceuticals & healthcare | 04/06/2018
Rights issue to reach several R&D events
Update | Pharmaceuticals & healthcare | 05/03/2018
Two new trials and likely out-licensing in 2018
Update | Pharmaceuticals & healthcare | 14/12/2017
R&D progress on track; new investor on board
Update | Pharmaceuticals & healthcare | 25/08/2017
Mitochondrial medicine specialist
Initiation | Pharmaceuticals & healthcare | 29/06/2017
Latest video
Industry outlook
NeuroVive has a diversified portfolio with all assets aimed at improving mitochondrial metabolism and function. This puts NeuroVive among the very few experts in mitochondrial medicine in the industry, in our view.
Last updated on 01/02/2019
Key management
| Erik Kinnman, CEO |
| Catharina Jz Johansson, CFO |
| Magnus Hansson , Chief Medical Officer |
| Daniel Schale, Director of Communications |
Company address
| Medicon Village Scheelevägen 2, Lund SE-223 81 Sweden 46 4 62 75 62 20 View website |